Journal of Microbiology, Immunology and Infection, 2022 Background: Imipenem-relebactam is a new β-lactam and β-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However, difference in carbapenem resistant mechanisms existed with geographic variations. Objective:
I-Ling Lin +2 more
exaly +3 more sources
Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
Antibiotics, 2021 (1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models.
Soo Min Jang, Michael Dean
exaly +3 more sources
Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies [PDF]
Antimicrobial Agents and ChemotherapyCeftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are key therapeutic options for infections caused by KPC-producing Klebsiella pneumoniae (KPC-Kp).
Marta Hernández-García +8 more
doaj +2 more sources
International Journal of Infectious Diseases, 2019 Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin.
Katherine Young, Pratik Bhagunde
exaly +3 more sources
Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024 [PDF]
Frontiers in Cellular and Infection MicrobiologyObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Mark G. Wise +5 more
doaj +2 more sources
Current Therapeutic Research: Background: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from Klebsiella pneumoniae.
Davood Mansury
exaly +3 more sources
Imipenem/cilastatin/relebactam dosing regimen justification using exposure–efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study [PDF]
Antimicrobial Agents and ChemotherapyAn exposure–efficacy analysis of the phase 3 RESTORE-IMI 2 study (NCT02493764) evaluated the relationship between plasma exposure of imipenem and relebactam and key efficacy endpoints (primary: 28-day all-cause mortality [ACM]; secondary: clinical ...
Munjal Patel +7 more
doaj +2 more sources
Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE) [PDF]
Antimicrobial Agents and ChemotherapyImipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa, but real-world effectiveness data are limited.
Walaiporn Wangchinda +21 more
doaj +2 more sources
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Journal of Global Antimicrobial ResistanceWe assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support.
Jae Min +2 more
exaly +3 more sources
Biomedicines, 2022 The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations.
Maria V. Golikova +7 more
doaj +1 more source